From CNBC:

Eli Lilly and Novo Nordisk face continued supply issues for their weight loss and diabetes drugs. Eli Lilly has doubled capacity and expects significant production increases by the second half of 2024. Meanwhile, Novo Nordisk’s recent acquisition of Catalent aims to unlock supply and improve the quality of its weight loss drug, Wegovy.

Elon Musk’s startup Neuralink has implanted its brain-computer interface into a human patient for the first time. The brain implant is designed to help patients with paralysis control external technologies using only their mind. Several other companies are also working on similar capabilities, with Synchron recently acquiring a German manufacturer to ramp up production.

Neuralink’s milestone marks the start of its first in-human clinical trial. The road to market will require further trials to prove safety and efficacy. Competing companies like Synchron are also preparing for commercial demand, with plans to produce their brain-computer interface in high volumes to help millions of people with paralysis.



Read more: Novo Nordisk, Eli Lilly tackle weight loss drug supply woes